Erelzi<sup>®</sup> – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)

Introduction of biosimilars of biological disease-modifying antirheumatic drugs (bDMARs) into clinical practice has significantly expanded the availability of bDMARD therapy for a wide range of patients with chronic immuno-inflammatory diseases.In 2020, the first biosimilar etanercept Erelzi®, was r...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: V. I. Mazurov, A. M. Lila, T. V. Korotaeva
Formato: Artigo
Lenguaje:Russo
Publicado: IMA-PRESS LLC 2021-08-01
Colección:Современная ревматология
Materias:
rheumatic diseases
psoriasis
biosimilars of biological disease-modifying antirheumatic drugs
etanercept
erelzi<sup>®</sup>
Acceso en línea:https://mrj.ima-press.net/mrj/article/view/1183
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares